{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:57:37Z","timestamp":1793757457972,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.critrevonc.2022.103751","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T12:02:41Z","timestamp":1655899361000},"page":"103751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models"],"prefix":"10.1016","volume":"176","author":[{"given":"Deepti","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sarwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hifzur R.","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2022.103751_bib1","article-title":"Chemotherapeutic effects of Apigenin in breast cancer: pre-clinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles","volume":"34","author":"Adel","year":"2022","journal-title":"Biotechnol. Rep."},{"key":"10.1016\/j.critrevonc.2022.103751_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/IJN.S285392","article-title":"SnO2-doped ZnO\/reducedgraphene oxide nanocomposites: synthesis, characterization, and improved anticancer activity via oxidative stress pathway","volume":"16","author":"Ahamed","year":"2021","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.critrevonc.2022.103751_bib3","doi-asserted-by":"crossref","first-page":"100216","DOI":"10.18632\/oncotarget.22145","article-title":"Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-\u03baB signaling","volume":"8","author":"Ai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103751_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1535-7163.MCT-11-0343","article-title":"Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo","volume":"11","author":"Budhraja","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103751_bib5","doi-asserted-by":"crossref","first-page":"187e198","DOI":"10.1007\/s12031-013-9975-x","article-title":"Sequential hTERT knockdown and apigenin treatment inhibited invasion and proliferation and induced apoptosis in human malignant neuroblastoma SK-N-DZ and SK-N-BE2 cells","volume":"51","author":"Chakrabarti","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.critrevonc.2022.103751_bib6","doi-asserted-by":"crossref","first-page":"35468","DOI":"10.1038\/srep35468","article-title":"Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4\/DR5 expression in a p53-dependent manner","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2022.103751_bib7","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3389\/fphar.2019.01614","article-title":"Phytochemicals in cancer treatment: from preclinical studies to clinical practice","volume":"10","author":"Choudhari","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2022.103751_bib8","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1021\/acsabm.8b00441","article-title":"Aptamer-conjugated apigenin nanoparticles to target colorectal carcinoma: a promising safe alternative of colorectal cancer chemotherapy","volume":"1","author":"Dutta","year":"2018","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.critrevonc.2022.103751_bib9","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/carcin\/bgt108","article-title":"Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402\/ADM cells to doxorubicin via inhibiting PI3K\/Akt\/Nrf2 pathway","volume":"34","author":"Gao","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2022.103751_bib10","first-page":"82085","article-title":"Apigenin sensitizes BEL-7402\/ADM cells to doxorubicin through inhibiting miR-101\/Nrf2 pathway","volume":"8","author":"Gao","year":"2017"},{"key":"10.1016\/j.critrevonc.2022.103751_bib11","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/onc.2013.207","article-title":"Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model","volume":"32","author":"Henkels","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2022.103751_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.biopha.2018.03.111","article-title":"Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling","volume":"102","author":"Hu","year":"2018","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2022.103751_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12935-021-01888-x","article-title":"Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment","volume":"21","author":"Javed","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2022.103751_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2021.05.019","article-title":"Luteolin and its derivative Apigenin suppress the inducible PD-L1 expression to improve antitumor immunity in KRAS-mutant lung cancer","volume":"515","author":"Jiang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2022.103751_bib15","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.2147\/IJN.S140096","article-title":"Synergistic apoptotic effects of Apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer","volume":"12","author":"Jin","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.critrevonc.2022.103751_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105892","article-title":"Revisiting inorganic nanoparticles as promising therapeutic agents: a paradigm shift in oncological theranostics","volume":"164","author":"Khan","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.critrevonc.2022.103751_bib17","first-page":"1","article-title":"Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol","author":"Khan","year":"2022","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.critrevonc.2022.103751_bib18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/jcbfm.2010.220","article-title":"Animal research: reporting in vivo experiments--the ARRIVE guidelines","volume":"31","author":"Kilkenny","year":"2011","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.critrevonc.2022.103751_bib19","doi-asserted-by":"crossref","DOI":"10.4062\/biomolther.2012.20.1.062","article-title":"Apigenin sensitizes Huh-7 human hepatocellular carcinoma cells to TRAIL induced apoptosis","volume":"20","author":"Kim","year":"2012","journal-title":". Biomol. Ther."},{"key":"10.1016\/j.critrevonc.2022.103751_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bbamcr.2011.12.008","article-title":"Evidence for activation of mutated p53 by Apigenin in human pancreatic cancer","volume":"1823","author":"King","year":"2012","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.critrevonc.2022.103751_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbrc.2017.04.029","article-title":"Application of molecular imaging technology in evaluating the inhibiting effect of Apigenin in vivo on subcutaneous hepatocellular carcinoma","volume":"487","author":"Li","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2022.103751_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1142\/S2575900018500131","article-title":"Combination of baicalein and docetaxel additively inhibits the growth of non-small cell lung cancer in vivo","volume":"01","author":"Lu","year":"2018","journal-title":"Tradit. Med. Mod. Med.."},{"key":"10.1016\/j.critrevonc.2022.103751_bib23","article-title":"Chemophototherapy: an emerging treatment option for solid tumors","volume":"4","author":"Luo","year":"2016","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.critrevonc.2022.103751_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317728480","article-title":"Antitumor and radiosensitizing synergistic effects of Apigenin and cryptotanshinone against solid Ehrlich carcinoma in female mice","volume":"39","author":"Medhat","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.critrevonc.2022.103751_bib25","doi-asserted-by":"crossref","first-page":"19834","DOI":"10.18632\/oncotarget.15771","article-title":"Apigenin inhibits renal cell carcinoma cell proliferation","volume":"8","author":"Meng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103751_bib26","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.neo.2018.07.005","article-title":"Apigenin inhibits UVB-induced skin carcinogenesis: the role of thrombospondin-1 as an anti-inflammatory factor","volume":"20","author":"Mirzoeva","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2022.103751_bib27","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1166\/jbn.2013.1704","article-title":"Micelles of TPGS modified apigenin phospholipid complex for oral administration: preparation, in vitro and in vivo evaluation","volume":"9","author":"Munyendo","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.critrevonc.2022.103751_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170197","article-title":"Apigenin: selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer","volume":"12","author":"Nelson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2022.103751_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.critrevonc.2022.103751_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173810","article-title":"H19-Wnt\/\u03b2-catenin regulatory axis mediates the suppressive effects of Apigenin on tumor growth in hepatocellular carcinoma","volume":"893","author":"Pan","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.critrevonc.2022.103751_bib31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/mc.20866","article-title":"Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study","volume":"51","author":"Pandey","year":"2012","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.critrevonc.2022.103751_bib32","doi-asserted-by":"crossref","first-page":"41421","DOI":"10.18632\/oncotarget.9404","article-title":"Apigenin inhibits NF-\u03baB and snail signaling, EMT and metastasis in human hepatocellular carcinoma","volume":"7","author":"Qin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2022.103751_bib33","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/ijms20061305","article-title":"The therapeutic potential of apigenin","volume":"20","author":"Salehi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2022.103751_bib34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3892\/or.2017.5752","article-title":"Apigenin overcomes drug resistance by blocking the signal transducer and activator of transcription 3 signaling in breast cancer cells","volume":"38","author":"Seo","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2022.103751_bib35","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2022.103751_bib36","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1535-7163.MCT-13-0066","article-title":"Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263","volume":"12","author":"Shao","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2022.103751_bib37","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.freeradbiomed.2008.02.007","article-title":"Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation","volume":"44","author":"Shukla","year":"2008","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.critrevonc.2022.103751_bib38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10495-014-0971-6","article-title":"Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer","volume":"19","author":"Shukla","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.critrevonc.2022.103751_bib39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/B978-0-323-90572-5.00027-5","article-title":"Targeting metabolism with herbal therapy: a preventative approach toward cancer","author":"Singh","year":"2022","journal-title":"J. Herbal Med."},{"key":"10.1016\/j.critrevonc.2022.103751_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/1574892814666191026095728","article-title":"Apigenin, a plant flavone playing noble roles in cancer prevention via modulation of key cell signaling networks","volume":"14","author":"Singh","year":"2019","journal-title":"Recent Pat. Anticancer Drug Disco"},{"key":"10.1016\/j.critrevonc.2022.103751_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120008","article-title":"Therapeutic implications of probiotics in microbiota dysbiosis: a special reference to the liver and oral cancers","volume":"285","author":"Singh","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2022.103751_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcdb.2021.04.003","article-title":"Role of p53-miRNAs circuitry in immune surveillance and cancer development: a potential avenue for therapeutic intervention","volume":"124","author":"Singh","year":"2022","journal-title":"Semin Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2022.103751_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114955","article-title":"Specific targeting of cancer stem cells by immunotherapy: a possible stratagem to restrain cancer recurrence and metastasis","volume":"198","author":"Singh","year":"2022","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.critrevonc.2022.103751_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116072","article-title":"Apigenin alleviates cancer drug Sorafenib induced multiple toxic effects in Swiss albino mice via anti-oxidative stress","volume":"447","author":"Singh","year":"2022","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.critrevonc.2022.103751_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.oooo.2013.10.012","article-title":"Impact of apigenin and kaempferol on human head and neck squamous cell carcinoma. oral surg oral med oral pathol","volume":"117","author":"Swanson","year":"2014","journal-title":"Oral. Radio."},{"key":"10.1016\/j.critrevonc.2022.103751_bib46","doi-asserted-by":"crossref","first-page":"323e330","DOI":"10.1080\/17425255.2017.1251903","article-title":"Pharmacokinetic properties and drug interactions of Apigenin, a natural flavone","volume":"13","author":"Tang","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.critrevonc.2022.103751_bib47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.taap.2013.05.028","article-title":"Apigenin suppresses migration and invasion of transformed cells through down-regulation of C-X-C chemokine receptor 4 expression","volume":"272","author":"Wang","year":"2013","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.critrevonc.2022.103751_bib48","article-title":"Apigenin inhibits the growth of hepatocellular carcinoma cells by affecting the expression of microRNA transcriptome","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2022.103751_bib49","volume":"2020","year":"2020"},{"key":"10.1016\/j.critrevonc.2022.103751_bib50","first-page":"1615","article-title":"Apigenin inhibits proliferation of human chondrosarcoma cells via cell cycle arrest and mitochondrial apoptosis induced by ROS generation-an in vitro and in vivo study","volume":"11","author":"Yan","year":"2018","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2022.103751_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102144","article-title":"Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells","volume":"47","author":"Yang","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.critrevonc.2022.103751_bib52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","article-title":"Inhibition of PI3K\/Akt\/mTOR pathway by Apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells","volume":"103","author":"Yang","year":"2018","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2022.103751_bib53","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/j.ejca.2010.07.007","article-title":"Molecular targets of Apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53","volume":"46","author":"Zhong","year":"2010","journal-title":"Eur. J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:43:03Z","timestamp":1760902983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":53,"alternative-id":["S1040842822001755"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103751","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103751"}}